HomeCompareAPLIF vs ADC

APLIF vs ADC: Dividend Comparison 2026

APLIF yields 18181.82% · ADC yields 4.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 APLIF wins by $20382968138483965952.00M in total portfolio value
10 years
APLIF
APLIF
● Live price
18181.82%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20382968138483965952.00M
Annual income
$20,164,798,479,641,134,000,000,000.00
Full APLIF calculator →
ADC
Agree Realty Corporation
● Live price
4.13%
Share price
$74.97
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$178.9K
Annual income
$80,797.29
Full ADC calculator →

Portfolio growth — APLIF vs ADC

📍 APLIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAPLIFADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, APLIF + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
APLIF pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

APLIF
Annual income on $10K today (after 15% tax)
$1,545,454.55/yr
After 10yr DRIP, annual income (after tax)
$17,140,078,707,694,964,000,000,000.00/yr
ADC
Annual income on $10K today (after 15% tax)
$351.36/yr
After 10yr DRIP, annual income (after tax)
$68,677.70/yr
At 15% tax rate, APLIF beats the other by $17,140,078,707,694,964,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of APLIF + ADC for your $10,000?

APLIF: 50%ADC: 50%
100% ADC50/50100% APLIF
Portfolio after 10yr
$10191484069241982976.00M
Annual income
$10,082,399,239,820,567,000,000,000.00/yr
Blended yield
98.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

APLIF
No analyst data
Altman Z
-234.9
Piotroski
4/9
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+8.1% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

APLIF buys
0
ADC buys
0
No recent congressional trades found for APLIF or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAPLIFADC
Forward yield18181.82%4.13%
Annual dividend / share$2.00$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$20382968138483965952.00M$178.9K
Annual income after 10y$20,164,798,479,641,134,000,000,000.00$80,797.29
Total dividends collected$20368560651224936448.00M$156.7K
Payment frequencyquarterlymonthly
SectorStockREIT

Year-by-year: APLIF vs ADC ($10,000, DRIP)

YearAPLIF PortfolioAPLIF Income/yrADC PortfolioADC Income/yrGap
1← crossover$1,828,882$1,818,181.82$10,990$580.36+$1.82MAPLIF
2$312,726,966$310,770,062.56$12,301$860.26+$312.71MAPLIF
3$49,997,862,140$49,663,244,286.24$14,104$1,298.62+$49997.85MAPLIF
4$7,474,070,205,933$7,420,572,493,443.65$16,691$2,008.16+$7474070.19MAPLIF
5$1,044,712,232,322,833$1,036,714,977,202,484.10$20,580$3,205.09+$1044712232.30MAPLIF
6$136,547,911,758,351,100$135,430,069,669,765,680.00$26,754$5,330.02+$136547911758.32MAPLIF
7$16,689,313,388,956,088,000$16,543,207,123,374,653,000.00$37,196$9,345.14+$16689313388956.05MAPLIF
8$1,907,542,220,817,720,100,000$1,889,684,655,491,537,200,000.00$56,244$17,523.09+$1907542220817720.25MAPLIF
9$203,896,877,423,206,970,000,000$201,855,807,246,932,000,000,000.00$94,286$35,736.21+$203896877423206976.00MAPLIF
10$20,382,968,138,483,967,000,000,000$20,164,798,479,641,134,000,000,000.00$178,949$80,797.29+$20382968138483965952.00MAPLIF

APLIF vs ADC: Complete Analysis 2026

APLIFStock

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

Full APLIF Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this APLIF vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

APLIF vs SCHDAPLIF vs JEPIAPLIF vs OAPLIF vs KOAPLIF vs MAINAPLIF vs NNNAPLIF vs EPRTAPLIF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.